The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
| Actual Study Start Date : | July 27, 2020 |
| Estimated Primary Completion Date : | October 27, 2022 |
| Estimated Study Completion Date : | October 27, 2022 |